Scientific basis for the potential use of melatonin in bone diseases: osteoporosis and adolescent idiopathic scoliosis.

Author(s):

Sánchez-Barceló EJ, Mediavilla MD, Tan DX, Reiter RJ

Keywords:

Categories:

Publication:

J Osteoporos. 2010 Jun 1;2010:830231.

Publication Link:

DOI Link:

https://doi.org/10.4061/2010/830231

The objective of this paper was to analyze the data supporting the possible role of melatonin on bone metabolism and its repercussion in the etiology and treatment of bone pathologies such as the osteoporosis and the adolescent idiopathic scoliosis (AIS). Melatonin may prevent bone degradation and promote bone formation through mechanisms involving both melatonin receptor-mediated and receptor-independent actions.

The three principal mechanisms of melatonin effects on bone function could be:

    • (a) the promotion of the osteoblast differentiation and activity;
    • (b) an increase in the osteoprotegerin expression by osteoblasts, thereby preventing the differentiation of osteoclasts;
    • (c) scavenging of free radicals generated by osteoclast activity and responsible for bone resorption.

A variety of in vitro and in vivo experimental studies, although with some controversial results, point toward a possible role of melatonin deficits in the etiology of osteoporosis and AIS and open a new field related to the possible therapeutic use of melatonin in these bone diseases.

Effects of melatonin on bone metabolism: A) Melatonin stimulates osteoblast proliferation and the synthesis of osteoprotegerin, which inhibits osteoclast differentiation by preventing the binding of ODF (osteoclast differentiation factor) with the RANK on osteoclasts. B) Melatonin inhibits osteoclast activity on the bones thanks to its radical scavenging property. (Modified from Cardinali et al.)
Scroll to Top